Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midazolam-ketamine versus propofol-sufentanil for procedural sedation in children with hematologic malignancy
IRCT20170809035601N8Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of midazolam, ketamine, propofol and sufentanil in hematopoietic malignancies and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Sedation level. Started Jun 2017; status: completed.
02
Drugs
midazolamketaminepropofolsufentanil
03
Conditions
hematopoietic malignanciesacute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on IRCT20170809035601N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170809035601N8.